AdV-tk基因介导细胞免疫治疗联合手术和放疗的儿童恶性胶质瘤及复发室管膜瘤I期研究
这是一项儿童脑肿瘤的I期剂量递增研究,评估AdV-tk基因介导细胞免疫治疗(GMCI)联合手术和放疗的安全性。8例患者(6例胶质母细胞瘤、1例间变性星形细胞瘤、1例复发室管膜瘤)接受瘤床注射AdV-tk后14天伐昔洛韦治疗,未出现剂量限制性毒性,常见不良事件为1-2级发热、乏力、恶心呕吐。3例剂量Level 2患者生存超过24个月。
要点
- GMCI联合放疗±替莫唑胺在儿童脑肿瘤患者中可安全实施,未出现剂量限制性毒性。
- 最常见可能与GMCI相关的不良事件为CTCAE 1-2级发热、乏力和恶心呕吐。
- 剂量Level 2有3例患者生存超过24个月,其中2例无进展存活37.3和47.7个月。
核心结论
- GMCI可安全联合放疗(联合或不联合替莫唑胺)用于儿童脑肿瘤患者,结果强烈支持进一步研究。
研究设计与样本
- I期剂量递增研究,纳入3岁及以上恶性胶质瘤或复发室管膜瘤患者,AdV-tk剂量为1×10^11和3×10^11载体颗粒(vp),术中注射至瘤床后予14天伐昔洛韦。
- 共8例患者入组并完成治疗:剂量Level 1为3例,剂量Level 2为5例;中位年龄12.5岁(范围7-17),Lansky/Karnofsky体能评分60-100。
主要发现
- 8例患者中6例胶质母细胞瘤、1例间变性星形细胞瘤、1例复发室管膜瘤;5例为多灶/广泛肿瘤未能完全切除,3例为全切除。
- 未出现剂量限制性毒性;最常见可能与GMCI相关的不良事件为CTCAE 1-2级发热、乏力和恶心呕吐。
- 剂量Level 2有3例患者生存超过24个月,其中2例在AdV-tk注射后37.3和47.7个月仍无进展存活。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Gene-mediated cytotoxic immunotherapy (GMCI) is a tumor-specific immune stimulatory strategy implemented through local delivery of aglatimagene besadenovec (AdV-tk) followed by anti-herpetic prodrug. GMCI induces T-cell dependent tumor immunity and synergizes with radiotherapy. Clinical trials in adult malignant gliomas demonstrated safety and potential efficacy. This is the first trial of GMCI in pediatric brain tumors. METHODS: This phase I dose escalation study was conducted to evaluate GMCI in patients 3 years of age or older with malignant glioma or recurrent ependymoma. AdV-tk at doses of 1 × 1011 and 3 × 1011 vector particles (vp) was injected into the tumor bed at the time of surgery followed by 14 days of valacyclovir. Radiation started within 8 days of surgery, and if indicated, chemotherapy began after completion of valacyclovir. RESULTS: Eight patients (6 glioblastoma, 1 anaplastic astrocytoma, 1 recurrent ependymoma) were enrolled and completed therapy: 3 on dose level 1 and 5 on dose level 2. Median age was 12.5 years (range 7-17) and Lansky/Karnofsky performance scores were 60-100. Five patients had multifocal/extensive tumors that could not be resected completely and 3 had gross total resection. There were no dose-limiting toxicities. The most common possibly GMCI-related adverse events included Common Terminology Criteria for Adverse Events grade 1-2 fever, fatigue, and nausea/vomiting. Three patients, in dose level 2, lived more than 24 months, with 2 alive without progression 37.3 and 47.7 months after AdV-tk injection. CONCLUSIONS: GMCI can be safely combined with radiation therapy with or without temozolomide in pediatric patients with brain tumors and the present results strongly support further investigation. CLINICAL TRIAL REGISTRY: ClinicalTrials.gov NCT00634231.
引用
- Kieran MW, Goumnerova L, Manley P, et al. Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma. Neuro Oncol. 2019. PMID: 30883662. doi:10.1093/neuonc/noy202
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。